KemPharm appoints Richard Pascoe as CEO; Travis Mickle resigns as CEO and President

ZEVRA THERAPEUTICS, INC.

Richard W. Pascoe appointed CEO effective Jan 6, 2023; steps down as Executive Chairman.
Travis C. Mickle resigns as CEO (immediate) and as President and board member (at 2023 annual meeting).
Pascoe's base salary increased to $592,000, target bonus 55%, granted option for 700,000 shares.
Mickle receives severance (18 months base salary, COBRA, pro-rata bonus), accelerated option vesting, and consulting agreement ($40k/month + 547,945 performance RSUs).
Matthew R. Plooster appointed Chairman of the Board.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew R. Plooster

Chairman of the Board

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-01-06
Filed: January 9, 2023, 6:59 PM ET

Additionally, the Board has appointed Matthew R. Plooster, a member of the Board, as the Chairman of the Board.

Role change

Richard W. Pascoe

Chief Executive Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-01-06
Filed: January 9, 2023, 6:59 PM ET

On January 6, 2023, the Board of Directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Richard W. Pascoe to serve as the Company’s Chief Executive Officer, effective immediately.

Departed

Travis C. Mickle

Chief Executive Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-01-06
Successor: Richard W. Pascoe
Filed: January 9, 2023, 6:59 PM ET

On January 6, 2023, Dr. Mickle resigned his role (i) as Chief Executive Officer, effective immediately, and (ii) as President and as a member of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew R. Plooster was appointed as Chairman of the Board at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Chairman of the Board

Exact text from the filing

Additionally, the Board has appointed Matthew R. Plooster, a member of the Board, as the Chairman of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard W. Pascoe was appointed as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: Chief Executive Officer

Exact text from the filing

On January 6, 2023, the Board of Directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Richard W. Pascoe to serve as the Company’s Chief Executive Officer, effective immediately.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Travis C. Mickle resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On January 6, 2023, Dr. Mickle resigned his role (i) as Chief Executive Officer, effective immediately, and (ii) as President and as a member of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-000695

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.